LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Начало・Списък с акции・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Затворен

СекторЗдравеопазване

12.75 6.07

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.81

Максимум

12.93

Ключови измерители
By Trading Economics
Приходи	4.4M -18M
Продажби	3.4M 18M
Марж на печалбата	-99.678
Служители	131
EBITDA	5.6M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+40.96% upside

Дивиденти
By Dow Jones
Следващи печалби	24.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	193M 332M
Предишно отваряне	6.68
Предишно затваряне	12.75

Настроения в новините

By Acuity

30%

70%

78 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

5.04 / 5.44 Подкрепа & съпротива

ENANTA PHARMACEUTICALS INC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.11.2025 г., 18:59 ч. UTC

Значими двигатели на пазара

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17.11.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Consolidates Amid Mixed Signals -- Market Talk

17.11.2025 г., 23:34 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17.11.2025 г., 22:58 ч. UTC

Пазарно говорене

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17.11.2025 г., 22:46 ч. UTC

Пазарно говорене

Risk Assets Set to Have a Strong 2026 -- Market Talk

17.11.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17.11.2025 г., 22:02 ч. UTC

Печалби

Trip.com Group 3Q Rev $2.6B >TCOM

17.11.2025 г., 22:02 ч. UTC

Печалби

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17.11.2025 г., 22:02 ч. UTC

Печалби

Trip.com Group 3Q EPS $4.02 >TCOM

17.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.11.2025 г., 21:40 ч. UTC

Печалби

James Hardie Industries 2Q Adj EPS 26c >JHX

17.11.2025 г., 21:40 ч. UTC

Печалби

James Hardie Industries 2Q Loss/Shr 10c >JHX

17.11.2025 г., 21:39 ч. UTC

Печалби

James Hardie Industries 2Q Sales $1.29B >JHX

17.11.2025 г., 21:38 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17.11.2025 г., 21:38 ч. UTC

Печалби

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17.11.2025 г., 21:10 ч. UTC

Печалби

XP Inc. 3Q EPS BRL2.47 >XP

17.11.2025 г., 21:10 ч. UTC

Печалби

XP Inc. 3Q Rev BRL4.67B >XP

17.11.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17.11.2025 г., 20:12 ч. UTC

Пазарно говорене

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17.11.2025 г., 20:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.11.2025 г., 20:09 ч. UTC

Пазарно говорене

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17.11.2025 г., 19:29 ч. UTC

Пазарно говорене

Gold Slide Continues to Start Week -- Market Talk

17.11.2025 г., 19:16 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17.11.2025 г., 18:20 ч. UTC

Придобивния, сливания и поглъщания

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17.11.2025 г., 16:45 ч. UTC

Придобивния, сливания и поглъщания

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17.11.2025 г., 16:16 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17.11.2025 г., 16:15 ч. UTC

Печалби

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17.11.2025 г., 15:40 ч. UTC

Придобивния, сливания и поглъщания

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17.11.2025 г., 15:22 ч. UTC

Придобивния, сливания и поглъщания

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17.11.2025 г., 15:19 ч. UTC

Пазарно говорене

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

ENANTA PHARMACEUTICALS INC Прогноза

Ценова цел

By TipRanks

40.96% нагоре

12-месечна прогноза

Среден 17 USD 40.96%

Висок 24 USD

Нисък 9 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за ENANTA PHARMACEUTICALS INC през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на ENANTA PHARMACEUTICALS INC през последните 3 месеца.

Техническа оценка

By Trading Central

5.04 / 5.44Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There are no events.

Настроение

By Acuity

78 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.